- Home
- ANTA vs CYPH Comparison
ANTA vs CYPH Comparison
Compare ANTA & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | CYPH |
|---|---|---|
| Founded | 2022 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.2M | 73.3M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ANTA | CYPH |
|---|---|---|
| Price | $2.33 | $3.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.17 | N/A |
| AVG Volume (30 Days) | 4.7K | ★ 16.1M |
| Earning Date | 06-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 103.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,500,000.00 |
| Revenue This Year | $21.95 | N/A |
| Revenue Next Year | $30.46 | N/A |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $0.49 |
| 52 Week High | $13.82 | $4.19 |
Technical Indicators
Market Signals| Indicator | ANTA | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 26.33 | 58.39 |
| Support Level | N/A | $0.69 |
| Resistance Level | $4.19 | $3.23 |
| Average True Range (ATR) | 0.28 | 0.50 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 3.86 | 53.86 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
About CYPH Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.